Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|July 2, 2021
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an OverviewMattias F Lindberg, Laurent Meijer
Neurobiology of Disease|April 16, 2026
DYRK1A and Parkinson's disease, facts and hypothesesLaurent Meijer, Mattias F Lindberg, Gaëlle Hogrel, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 iPSC-derived neural cellsNicole R West, Mattias F Lindberg, Julien Dairou, et al.
Disease Models & Mechanisms|June 29, 2026
Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cellsNicole R West, Mattias F Lindberg, Julien Dairou, et al.
International Journal of Pharmaceutics|May 26, 2016
Optimisation of vectorisation property: A comparative study for a secondary amphipathic peptideKaridia Konate, Mattias F Lindberg, Anaïs Vaissiere, et al.
Journal of Medicinal Chemistry|March 6, 2023
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein KinasesMattias F Lindberg, Emmanuel Deau, Jonas Arfwedson, et al.
Melanoma Research|November 10, 2021
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanomaVasu R Sah, Joakim Karlsson, Henrik Jespersen, et al.
Pharmaceuticals (Basel, Switzerland)|December 22, 2019
Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1ACorinne Fruit, Florence Couly, Rahul Bhansali, et al.
Journal of Medicinal Chemistry|July 24, 2023
Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine BEmmanuel Deau, Mattias F Lindberg, Frédéric Miege, et al.
Pageof 3